(PHN) Pharmanutra S.p.A - Overview
Stock: Supplements, Medical Devices, Raw Materials, Nutraceuticals, Bioimpedance
| Risk 5d forecast | |
|---|---|
| Volatility | 29.5% |
| Relative Tail Risk | -17.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 18.91 |
| Character TTM | |
|---|---|
| Beta | 0.025 |
| Beta Downside | 0.044 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.75% |
| CAGR/Max DD | 0.12 |
EPS (Earnings per Share)
Revenue
Description: PHN Pharmanutra S.p.A February 19, 2026
Pharmanutra S.p.A. (MI:PHN) is an Italian-based pharma and nutraceutical firm founded in 2003 in Pisa. It develops, manufactures, and markets a portfolio that spans nutritional supplements, medical devices, and raw-material ingredients for the food, pharmaceutical, and dietary-supplement sectors, serving customers across Europe, the Middle East, South America, the Far East and online channels.
According to the company’s 2023 annual report, Pharmanutra generated €112 million in revenue, up 7 % year-over-year, with an adjusted EBITDA margin of 12 % and a cash-conversion cycle of 45 days. The firm’s R&D spend averaged 5.5 % of sales in 2023, reflecting a continued focus on product innovation in iron-deficiency and sports-nutrition categories.
Key drivers for Pharmanutra’s market include (1) the global nutraceutical market, projected to grow at a 7.5 % CAGR through 2028, (2) an aging European population that is increasing demand for joint-health and ophthalmic supplements, and (3) tightening EU regulations on health claims, which raise barriers to entry and favor established players with compliant pipelines. Conversely, currency volatility in the Eurozone and supply-chain constraints on raw-material inputs introduce downside risk.
For a deeper quantitative assessment, you may want to explore the detailed valuation model on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 17.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -8.10 > 1.0 |
| NWC/Revenue: 28.91% < 20% (prev 31.22%; Δ -2.31% < -1%) |
| CFO/TA 0.12 > 3% & CFO 14.4m > Net Income 17.4m |
| Net Debt (4.73m) to EBITDA (32.9m): 0.14 < 3 |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (9.59m) vs 12m ago -0.18% < -2% |
| Gross Margin: 82.56% > 18% (prev 0.63%; Δ 8193 % > 0.5%) |
| Asset Turnover: 108.7% > 50% (prev 97.98%; Δ 10.76% > 0%) |
| Interest Coverage Ratio: 37.87 > 6 (EBITDA TTM 32.9m / Interest Expense TTM 756.0k) |
Altman Z'' 4.32
| A: 0.31 (Total Current Assets 68.1m - Total Current Liabilities 31.1m) / Total Assets 119.8m |
| B: 0.12 (Retained Earnings 14.0m / Total Assets 119.8m) |
| C: 0.24 (EBIT TTM 28.6m / Avg Total Assets 117.7m) |
| D: 0.26 (Book Value of Equity 14.0m / Total Liabilities 53.7m) |
| Altman-Z'' Score: 4.32 = AA |
Beneish M -3.15
| DSRI: 0.97 (Receivables 26.9m/24.5m, Revenue 128.0m/113.3m) |
| GMI: 0.77 (GM 82.56% / 63.30%) |
| AQI: 0.98 (AQ_t 0.23 / AQ_t-1 0.23) |
| SGI: 1.13 (Revenue 128.0m / 113.3m) |
| TATA: 0.03 (NI 17.4m - CFO 14.4m) / TA 119.8m) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of PHN shares?
Over the past week, the price has changed by +6.66%, over one month by +2.82%, over three months by +31.14% and over the past year by +23.24%.
Is PHN a buy, sell or hold?
What are the forecasts/targets for the PHN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81 | 23.3% |
| Analysts Target Price | - | - |
PHN Fundamental Data Overview February 18, 2026
P/E Trailing = 29.3182
P/S = 4.8953
P/B = 9.3877
Revenue TTM = 128.0m EUR
EBIT TTM = 28.6m EUR
EBITDA TTM = 32.9m EUR
Long Term Debt = 14.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.61m EUR (from shortLongTermDebt, last quarter)
Debt = 19.5m EUR (Calculated: Short Term 4.61m + Long Term 14.9m)
Net Debt = 4.73m EUR (from netDebt column, last quarter)
Enterprise Value = 499.6m EUR (494.9m + Debt 19.5m - CCE 14.8m)
Interest Coverage Ratio = 37.87 (Ebit TTM 28.6m / Interest Expense TTM 756.0k)
EV/FCF = 47.93x (Enterprise Value 499.6m / FCF TTM 10.4m)
FCF Yield = 2.09% (FCF TTM 10.4m / Enterprise Value 499.6m)
FCF Margin = 8.15% (FCF TTM 10.4m / Revenue TTM 128.0m)
Net Margin = 13.63% (Net Income TTM 17.4m / Revenue TTM 128.0m)
Gross Margin = 82.56% ((Revenue TTM 128.0m - Cost of Revenue TTM 22.3m) / Revenue TTM)
Gross Margin QoQ = 76.58% (prev 77.53%)
Tobins Q-Ratio = 4.17 (Enterprise Value 499.6m / Total Assets 119.8m)
Interest Expense / Debt = 0.75% (Interest Expense 147.0k / Debt 19.5m)
Taxrate = 37.00% (2.81m / 7.60m)
NOPAT = 18.0m (EBIT 28.6m * (1 - 37.00%))
Current Ratio = 2.19 (Total Current Assets 68.1m / Total Current Liabilities 31.1m)
Debt / Equity = 0.29 (Debt 19.5m / totalStockholderEquity, last quarter 66.1m)
Debt / EBITDA = 0.14 (Net Debt 4.73m / EBITDA 32.9m)
Debt / FCF = 0.45 (Net Debt 4.73m / FCF TTM 10.4m)
Total Stockholder Equity = 63.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.83% (Net Income 17.4m / Total Assets 119.8m)
RoE = 27.48% (Net Income TTM 17.4m / Total Stockholder Equity 63.5m)
RoCE = 36.52% (EBIT 28.6m / Capital Employed (Equity 63.5m + L.T.Debt 14.9m))
RoIC = 21.28% (NOPAT 18.0m / Invested Capital 84.7m)
WACC = 5.80% (E(494.9m)/V(514.4m) * Re(6.01%) + D(19.5m)/V(514.4m) * Rd(0.75%) * (1-Tc(0.37)))
Discount Rate = 6.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈14.0m ; Y1≈9.21m ; Y5≈4.20m
Fair Price DCF = 13.46 (EV 133.8m - Net Debt 4.73m = Equity 129.1m / Shares 9.59m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 23.33 | EPS CAGR: 14.78% | SUE: 0.19 | # QB: 0
Revenue Correlation: 89.79 | Revenue CAGR: 15.64% | SUE: 2.58 | # QB: 3
EPS next Year (2026-12-31): EPS=2.35 | Chg30d=+0.037 | Revisions Net=-1 | Growth EPS=+18.4% | Growth Revenue=+14.0%